and recommendation
Sangamo Biosciences Inc. (SGMO)
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The companys principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimers disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntingtons disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- June 20, 2017 - 4:50pm | Research Notes, Financings
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- January 11, 2017 - 8:29am | Research Notes
- January 5, 2017 - 8:40am | Research Notes
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- September 6, 2016 - 8:09am | Research Notes
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- July 26, 2016 - 1:18pm | Research Notes
- June 20, 2016 - 10:16am | Research Notes
- June 1, 2016 - 9:32am | BOD & C-Suite Updates
- March 2, 2016 - 9:35am | Research Notes, Henry'omics
- February 25, 2016 - 8:44am | Research Notes, Henry'omics
- February 8, 2016 - 8:12am | Research Notes, Henry'omics
- December 7, 2015 - 9:23am | Research Notes
- November 16, 2015 - 10:34am | Earnings Q3
- September 21, 2015 - 11:09am | Research Notes, Regulatory
- September 10, 2015 - 8:22am | Research Notes, Regulatory
- July 1, 2015 - 9:42am | Research Notes